Year: 2018
Type: article
Abstract: Exercise interventions are generally well known to provide benefits for muscle strength and physical function. However, much remains unclear as to whether this same efficacy will also be shown in patients with sarcopenia. A meta-analysis of seven randomized clinical trials (RCT) was carried out on skeletal muscle mass data, the basic concept of sarcopenia.1 Based on the results, most of the RCT examined included data showing improvement in muscle strength2-6 and physical functions, such as gait,3-5, 7 whereas just three of these studies had data showing increased skeletal muscle mass.2, 4, 5 However, these RCT analyzed primarily older individuals residing locally whose conditions were also complicated by frailty,1 and whether the study conclusions can also be applied to older patients diagnosed with sarcopenia before any intervention is debatable. Therefore, focusing on RCT regarding patients with sarcopenia is necessary. In the systematic review carried out for this clinical question (CQ; Fig. 1),8 although RCT focusing on older patients who satisfied either the European Working group on Sarcopenia in Older People (EWGSOP) or Asian Working group for Sarcopenia (AWGS) diagnostic criteria for sarcopenia were targeted, not all of the RCT screened applied inclusion criteria requiring older patients diagnosed with sarcopenia based on either the EWGSOP or AWGS criteria, and as such, RCT included participants diagnosed with sarcopenia based on a combination of the amount of reduction in skeletal muscle mass and muscle strength/physical functions. Exercise interventions administered in three extracted RCT comprised a comprehensive training program, including 60-min resistance exercises carried out twice weekly for 3 months.9-11 Comparison against the control group who underwent nutritional intervention or health education showed that after the comprehensive training program, the appendicular skeletal muscle mass, normal gait speed, maximum gait speed and knee extension muscle strength were 0.38 kg, 0.11 m/s, 0.26 m/s, 0.11 Nm/kg and 8.55 Nm, respectively, each showing improvement.8 In contrast, no change in grip strength was observed as a result of the comprehensive training program.8 It is necessary to consider that although participants in this study were not diagnosed with sarcopenia based on established diagnostic criteria, such as the EWGSOP and AWGS, they were diagnosed using data showing decreased skeletal muscle mass. With regard to other exercise interventions, whole-body vibration training was found to be ineffective in improving the cross-sectional area of the quadriceps vastus medialis muscle and knee extension muscle strength compared with participants in the control group who did not engage in a training program.12 Based on the above results, undergoing exercise interventions for ≥3 months might help increase skeletal muscle mass, muscle strength and gait speed. However, one issue is that the criteria used for the diagnosis of sarcopenia before the intervention do not always match the most current established diagnostic criteria, and as such, numerous aspects of this topic remain at a very low evidence level. Further accumulation of clinical data will be necessary to clarify these issues. Nutritional interventions are strongly believed to offer benefits similar to those of exercise interventions in regard to muscle strength and physical functions. However, numerous unclear points still remain regarding whether nutritional interventions also have beneficial effects in patients with sarcopenia. A meta-analysis examined 12 RCT evaluating skeletal muscle mass data, which is the basis for diagnosing sarcopenia.1 This meta-analysis found that although improvement in physical functions, such as gait, was observed in three of these studies,9, 10, 13 increases in skeletal muscle mass14 and improvements in muscle strength15 were observed in one study, respectively. In addition, these RCT primarily examined older individuals, including frail older adults.1 As such, whether the conclusions reached as a result of these studies can also be applied to older patients diagnosed with sarcopenia before intervention is debatable. Therefore, focusing on RCT examining older patients with sarcopenia was determined to be necessary. The systematic review for this CQ examined five RCT (Fig. 2) focusing on older patients previously diagnosed with sarcopenia.8 The nutritional interventions carried out in these studies included the administration of 3 g essential amino acids twice daily,9 540 mg tea catechin supplement daily,10 3 g essential amino acids and 540 mg tea catechin daily,11 and 12 g protein and 7 g essential amino acids daily.16 As a nutritional intervention, essential amino acid supplementation was observed to be effective for improving knee extension muscle strength (0.11 Nm/kg 3 months after).9 However, no significant differences were observed with respect to skeletal muscle mass, fat-free mass (FFM), grip strength, knee extension muscle strength, gait speed or Timed Up and Go test performance,7, 17 which were examined in many combinations, including use of other nutritional supplementation methods. Considering that participants in these studies were diagnosed with sarcopenia based on the degree of decline in skeletal muscle mass rather than in accordance with established diagnostic criteria, such as the EWGSOP and AWGS, is necessary. The results of the above studies showed that nutritional interventions extending for at least 3 months might contribute to improvement in muscle strength. However, further studies investigating whether such interventions also affect skeletal muscle mass and physical functions are required. Another concern is that the criteria used to diagnose sarcopenia before intervention do not always match the most current established diagnostic criteria, and as such numerous aspects of this topic remain at a very low evidence level. Further accumulation of clinical data will be necessary to clarify these issues. Changes in the endocrine environment accompanying aging, decreases in skeletal muscle mass and muscle weakness are closely related. The body of evidence regarding the efficacy of drug therapy as a treatment for sarcopenia is currently inadequate. However, some reports showed that skeletal muscle mass and muscle strength both can increase as a result androgen supplementation therapy, but the participants in these studies were men showing decreased gonadal function and postmenopausal women18, 19 rather than older patients with sarcopenia. This CQ will pay particular attention to the results of review articles20 and studies verifying the ability of SARM to improve skeletal muscle mass and physical functions in healthy men and postmenopausal women.21 As such, this CQ will assess whether drug therapies can be effective for increasing skeletal muscle mass, muscle strength and physical functions in older patients with sarcopenia through a review of the results of the existing literature published to date. Based on the results of a systematic review and meta-analysis carried out to verify the therapeutic effects of drugs, 1011 articles were extracted, but only one article regarding verification of the efficacy of drug therapy as a treatment for sarcopenia in older patients could be found (Fig. 3).8 In 2013, Papanicolaou et al., carried out a randomized, double-blinded study in which 170 women aged >65 years with sarcopenia were assigned to either a group administered 50 mg SARM (MK-0773) or a placebo for 6 months, during which the participants were monitored with respect to changes in skeletal muscle mass and physical functional capacity.22 All participants received a placebo 14 days before the start of the study intervention, after which the participants were randomly assigned to either the MK-0773 or placebo group. All participants were also administered protein and vitamin D throughout the study period. The participants were administered 25–35 g/day protein supplementation from the start of the intervention, and 2800–5600 IU/day vitamin D 14 days before the start of the intervention. Changes in lean body mass (LBM) after 3 months were 1.00 kg (95% CI 0.59–1.41) greater in the MK-0773 group compared with the placebo group. In addition, the change in appendicular LBM was 0.56 kg (95% CI 0.35–0.78) greater in the MK-0773 group compared with the placebo group. Furthermore, changes in LBM and appendicular LBM after 6 months in the MK-0773 group were greater than those in the placebo group. However, leg press performance, gait speed and stair-climbing capacity increased in both groups, and no significant difference was observed between the MK-0773 and placebo groups with respect to these factors. As such, although significant changes in the LBM and appendicular LBM values were observed between the baseline and after 3 months, no significant increases were observed between the 3- and 6-month values. Based on the above results, although increased skeletal muscle mass was observed as a therapeutic effect of drugs administered to older patients with sarcopenia, increased muscle strength or gait speed was not observed. No report verified the therapeutic effects of drugs in men with sarcopenia. Based on this background, the evidence level available regarding the therapeutic effects of drugs in older patients with sarcopenia is low, and no medications can currently be affirmatively recommended as treatments for sarcopenia. Large-scale interventions of participant populations, including men, will be required in the future. We screened 315 articles regarding combined intervention approaches. As a result of a systematic review8 that meta-analyzed four articles (sample size 501) to verify the effects of combined interventions in three studies,9-11 a subgroup analysis, including studies comparing a combined intervention group against an exercise intervention only group, or a combined intervention group against a nutritional intervention only group, was carried out. In addition, an RCT by Zdzieblik et al., investigated older adults who engaged in 60-min resistance training using exercise machines thrice a week while receiving 15 g collagen peptide or a placebo for 3 months.17 A subgroup meta-analysis incorporating these four RCT was carried out to compare the effects of: (i) exercise intervention alone versus a combination of nutrition and exercise interventions; and (ii) combined exercise and nutritional intervention versus nutritional intervention alone. Although combined exercise + nutritional interventions tended to increase FFM after 3 months in the four RCT analyzed, no significant changes in appendicular skeletal muscle mass, grip strength, knee extension muscle strength or normal/maximum gait speed were observed (Fig. 4).8 In three of the RCT analyzed, combined exercise + nutritional interventions were found to be effective for improving knee extension muscle strength after 3 months. However, no significant changes were observed with respect to appendicular skeletal muscle mass, grip strength or normal/maximum gait speed (Fig. 5).8 Although the nature of any additive effects of exercise and nutritional interventions could not be clarified through this systematic review because the participants were primarily older patients presenting with decreased skeletal muscle mass + grip strength or decreased gait speed, Rondanelli et al., reported increased FFM and improved muscle strength in older patients with low skeletal muscle mass who were administered whey protein, essential amino acids and vitamin D supplementation for 12 weeks after all the participants had completed an exercise intervention.23 Accordingly, a combination of exercise and nutrition was considered to form the foundation of any effective therapeutic intervention for sarcopenia. Furthermore, although not sarcopenia, the ability of combined exercise and nutritional interventions to improve muscle strength has also been shown in patients with chronic obstructive pulmonary disease (COPD),24 frail older adults6 and patients with osteoporosis.25 No additive effects were observed in patients with sarcopenia as a result of exercise + nutritional interventions in this systematic review, and further accumulation of evidence regarding the content of exercise and nutritional interventions is required. Diseases leading to secondary sarcopenia include cancer, COPD, CKD, heart failure, osteoporosis and others. This assessment investigated whether improvement in the state of the primary disease was achieved following treatment interventions designed to address sarcopenia. First, few reports currently described the results of clinical trial results investigating the impact of improving sarcopenia in conjunction with cancer treatment. Supplementation with vitamin D or β-hydroxy-β-methylbutyric acid in cancer patients is effective for increasing or preventing decreases in muscle mass,26 whereas suitable amounts of exercise have been reported to potentially suppress loss of muscle mass during breast cancer treatment.27 In addition, in an RCT investigating 57 patients with prostate cancer undergoing androgen suppression therapy for >2 months, the patients were divided into a resistance + aerobic exercise group (29 patients) and a usual care group (28 patients), and were observed over a 12-week period. As a result, patients in the exercise group showed significant increases in skeletal muscle mass, (whole body, lower extremities, upper extremities), increased muscle strength and gait function compared with the usual care group.28 Respiratory rehabilitation and physical training to improve COPD have been shown to result in increases in bodyweight and skeletal muscle mass, as well as improved motor functions. In another study investigating the impact of amino acid supplementation, 32 patients aged >40 years with severe COPD complicated by sarcopenia were divided into a 4 g/b.i.d. amino acid group (16 patients) or a placebo group (16 patients), after which the degree of change in their conditions after 4 and 12 weeks was examined. As a result, compared with the placebo group, patients in the amino acid group showed a mean increase in bodyweight of 6 kg, a 3.6–kg increase in FFM, increased physical activity, improved cognitive function and improved overall health.29 Sarcopenia readily complicates CKD cases, and the prevalence of sarcopenia increases as the severity of CKD progresses to higher stages.30 Exercise, and amino acid and vitamin D supplementation are both effective for improving inactivity and sarcopenia symptoms in patients with CKD.31 In support of this observation, based on the results of another study in which 119 patients with stage 3 or 4 CKD were randomly selected and placed into a group undergoing exercise training (65 patients) or a usual care group (54 patients), and then followed for 12 weeks, the performance on the 6-min walk test improved by 19% in the exercise training group, whereas the performance decreased by 10% (P < 0.001) in the usual care group. In addition, the performance on the chair-stand test improved by 29% and 0.7% in the exercise training and usual care groups, respectively (P < 0.001). These results suggested that the exercise program was effective for improving the physical capacities and QOL of patients with CKD.32 Restriction of physical activity due to diminished cardiac function in patients with chronic heart failure can result in decreased muscle mass and muscle weakness, and sarcopenia occurs as a complication in approximately 20% of older patients with chronic heart failure.33 Although nutritional supplementation, exercise and hormone replacement therapy have been proposed as methods for improving sarcopenia and diminished cardiac function,34 others have highlighted the effect of a high-protein diet and/or amino acid supplementation to cause weight gain in patients with chronic heart failure,35 whereas exercise training has been shown to help reduce myostatin and improve aerobic capacity.36, 37 Although inadequate testosterone in patients with chronic heart failure has been associated with the onset of muscle weakness, such patients have shown improved gait functions and increased muscle strength as a result of testosterone supplementation.38 Although similar effects have been reported with regard to supplementation with human growth hormone, ghrelin and vitamin D, there is currently insufficient evidence regarding the effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and β-blockers in patients with sarcopenia. Osteoporosis is strongly associated with decreases in muscle mass and muscle strength. In a study of 131 men (mean age 77.1 ± 7.6 years) with a history of bone fractures, low bone density and low blood testosterone level, the participants were divided into either a group administered 5 mg/day testosterone supplementation or a placebo group, and were then observed for 12–24 months. As a result, femoral cervical and lumbar bone densities increased by 1.4% and 3.2%, respectively, in the testosterone-supplemented group. In addition, although muscle mass increased and body fat decreased in the testosterone-supplemented group, no differences in exercise capacity were observed compared with the placebo group.39 Furthermore, in another study in which 5 mg/day of alendronate and 0.5 μg/day of calcitriol were administered for 6 months to 38 women (mean age 56.0 ± 8.00 years) with decreased bone density, interleukin-6 levels, lumbar vertebral bone density and grip strength decreased by 56.5%, 2.62% and 33.5%, respectively. These findings clearly show that treatment with 5 mg/day of alendronate and calcitriol is effective for suppressing bone loss and increasing skeletal muscle mass in women presenting with reduced bone density.40 See Figures S1–S4 for literature flowchart. In the Sarcopenia clinical practice guidelines 2017 edition preparation committee, regarding the economic relationship between the committee members and the companies involved in sarcopenic diseases and sarcopenic diseases, each member gave declarations of the conflict of interest status in the past 3 years based on the following criteria. Remuneration of officers and advisory positions (¥ one million or more annually paid by a single company/organization), the possession of shares and the profit obtained from the stock (¥ one million or more of annual profit from one company or 5% or more of the total shares of the company), a fee paid as a royalty fee (one patent royalty of ¥ one million or more per year), a lecture fee (the annual sum total of ¥500 000 or more from one company/organization), manuscript (manuscript fee, daily allowance paid by one company/organization totaling more than ¥500 000), research expenses (total amount paid for one clinical study ¥ one million yen or more per year), donation (¥ one million or more per year by one company/organization), affiliation to a donated fund laboratory provided by a company and so on (if affiliated to the department), and other remuneration (an annual total of ¥50 000 or more rewards, such as gifts or trip unrelated to the studies provided by company/organization). All members of the committee are responsible for the contents of "Sarcopenia clinical practice guidelines 2017" as medical or medical specialists or specialists of sarcopenic diseases and related diseases, to ensure scientific and medical fairness and appropriateness, to extend the healthy lifespan of the target patient, and to improve quality of life. Regarding the treatment of conflicts of interest, it was in accordance with the Committee on Conflicts of Interest of Japan Medical Association "Guidelines on COI Management of Clinical Studies." The company names declared are as follows (the applicable period is 1 January 2014 to 31 December 2016). It does not include publishers and organizations in a neutral position. Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., ALCARE Co., Ltd.,Inter Reha Co., Ltd., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Kao Corporation, Kyowa Hakko Kirin CO., LTD., CLINICO CO., LTD., Kuredoru, Kowa Pharmaceutical Co.Ltd., SHIONOGI & CO., LTD., Sucampo Pharma, LLC, DAIICHI SANKYO COMPANY, LIMITED, Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., TSUKUI CORPORATION, TSUMURA & CO., TEIJIN PHARMA LIMITED., TOYOTA MOTOR CORPORATION, Eli Lilly Japan K.K., Boehringer Ingelheim, Nestle Japan Ltd., Novartis International AG, Bayer Yakuhin, Ltd., Pfizer Japan Inc., Bristol-Myers Squibb Company, HOYA CORPORATION, and MOCHIDA PHARMACEUTICAL. Figure S1 Process flow for selection of literature sources for the Chapter 4-CQ1 systematic review. Figure S2 Process flow for selection of literature sources for the Chapter 4-CQ2 systematic review. Figure S3 Process flow for selection of literature sources for the Chapter 4-CQ3 systematic review. Figure S4 Process flow for selection of literature sources for the Chapter 4-CQ4 systematic review. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
DOI: 10.1111/ggi.13322
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: sarcopenia, exercise intervention, resistance training, whole-body vibration training, muscle strength, physical function, walking speed, skeletal muscle mass, older adults, EWGSOP criteria, AWGS criteria, dietary intervention, grip strength, quadriceps strength, frailty, sarcopenia treatment
Open Access status: bronze
OpenAlex ID: W2802759229
